An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis

Phase 1

• Conditions: Idiopathic Pulmonary Fibrosis (IPF)

• Registration Number: EUCTR2004-001261-17-IE
• Lead Sponsor: InterMune

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-12-08
• Last Update Posted: 13 October 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Enrollment in Protocol GIPF-002 Part B or GIPF-004
2. Completion of the End of Treatment Visit in Protocol GIPF-002 Part B or the Study
Completion Visit in GIPF-004
3. Able to understand and sign a written informed consent form and comply with the
requirements of the study
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Pregnancy or lactation
2. Lack of adherence to GIPF-002 or GIPF-004 study protocol and treatment regimen
3. In the opinion of the Principal Investigator (PI), the patient is not a suitable candidate for study participation

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified